Jason Drew Smith Sells 7,522 Shares of Urogen Pharma (NASDAQ:URGN) Stock

Key Points

• Urogen Pharma's General Counsel, Jason Drew Smith, sold 7,522 shares of stock, totaling $143,971.08, reducing his ownership by 15.35% to approximately $794,156.88.
• The company's stock has a current price of $19.22 and has seen a significant trading volume with a 52-week range between $3.42 and $19.74.
• Several analysts have set target prices for Urogen Pharma, with estimates ranging from $16.00 to $50.00, predominantly maintaining a "buy" rating.

Urogen Pharma (NASDAQ:URGN - Get Free Report) General Counsel Jason Drew Smith sold 7,522 shares of the business's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $19.14, for a total transaction of $143,971.08. Following the transaction, the general counsel directly owned 41,492 shares in the company, valued at approximately $794,156.88. The trade was a 15.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Urogen Pharma Stock Performance

Shares of NASDAQ:URGN traded up $0.34 during midday trading on Friday, reaching $19.40. 1,007,965 shares of the company's stock traded hands, compared to its average volume of 1,598,013. Urogen Pharma has a 1 year low of $3.42 and a 1 year high of $19.74. The company has a market cap of $896.28 million, a P/E ratio of -6.10 and a beta of 1.02. The company has a fifty day simple moving average of $12.21 and a two-hundred day simple moving average of $10.96.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). The business had revenue of $20.25 million for the quarter, compared to analysts' expectations of $22.71 million. Urogen Pharma had a negative net margin of 150.68% and a negative return on equity of 97,487.15%. As a group, research analysts forecast that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on URGN shares. Scotiabank reissued an "outperform" rating on shares of Urogen Pharma in a report on Friday, June 13th. HC Wainwright restated a "buy" rating and issued a $50.00 price target on shares of Urogen Pharma in a research report on Tuesday, July 8th. Guggenheim reiterated a "buy" rating and set a $30.00 price objective (up previously from $15.00) on shares of Urogen Pharma in a research report on Friday, June 13th. D. Boral Capital restated a "buy" rating and issued a $25.00 price target on shares of Urogen Pharma in a report on Monday, July 7th. Finally, The Goldman Sachs Group set a $16.00 price objective on shares of Urogen Pharma and gave the stock a "neutral" rating in a research note on Friday, June 13th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Urogen Pharma currently has a consensus rating of "Buy" and a consensus target price of $32.86.

Hedge Funds Weigh In On Urogen Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Allianz Asset Management GmbH purchased a new stake in Urogen Pharma in the second quarter valued at approximately $203,000. Bender Robert & Associates acquired a new stake in Urogen Pharma in the second quarter valued at $475,000. Truist Financial Corp acquired a new stake in shares of Urogen Pharma during the second quarter valued at $423,000. Jane Street Group LLC boosted its stake in shares of Urogen Pharma by 94.3% during the first quarter. Jane Street Group LLC now owns 51,177 shares of the company's stock valued at $566,000 after acquiring an additional 24,839 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Urogen Pharma by 216.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company's stock worth $48,227,000 after buying an additional 2,983,368 shares during the period. Hedge funds and other institutional investors own 91.29% of the company's stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.